You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Diffused Optical Tomography using Oxygen-sensitive Luminescent Contrast Agent for

    SBC: RADIATION MONITORING DEVICES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Molecule specific targeting and improving image contrast have been recognized as important research areas in cancer imaging. Goal of cancer diagnosis and prognosis research is to develop new imaging techniques to detect lesions with certainty in early stages so that they can be treated. Developing biomarkers, which will signal the presence and the type of lesio ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal outlines a body of research to evaluate the cytotoxicity and therapeutic efficacy of radiolabeled alpha-melanocyte stimulating hormone (a-MSH) peptide analogs that target a-particle emitting radioisotopes to the nuclei of melanoma cells. The selective targeting of alpha-particle emitting radioisotopes for cancer therapy is emerging as an exciting ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. Processing Ac-227 sources for lead-212 and radium-223 required by cancer research

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radium-223 is being used in clinical trials in treatment of skeletal metastases. There is no effective therapy for these diseases. Together 199,280 ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced Tracking Techniques for FOPEN GMTI Radars

    SBC: ALPHATECH, INC.            Topic: N/A

    The utility of continuously tracking vehicles in a battlefield has been demonstrated during the Gulf War and other recent conflicts. However, the ability to achieve reliable continuous tracking in many environments will require the use of FOPEN radar andefficient use of sensor resources. In this effort we extend current research to include heterogeneous terrain and apply this model to simulations. ...

    STTR Phase I 2001 Department of DefenseDefense Advanced Research Projects Agency
  5. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. Alkylating Vitamin D Derivative

    SBC: APHIOS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer is the most prevalent cancer among men; and the second leading cause of cancer death among men in the US. There are currently no approved therapies for hormone-refractory prostate cancer. Epidemiological studies have demonstrated a strong relationship between incidence of and mortality from various cancers including prostate cancer, exposure to ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Neuroprotective Drugs for Spinal Cord Injury

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION: (Adapted from the Applicant's Abstract) Traumatic spinal cord injury (SCI) leads to permanent loss of motor function and control of function below the level of the injury. A significant portion of the loss is due to secondary factors rather than the initial trauma. These factors include increased extracellular concentrations of glutamate which ha ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. Neuroadaptive effects after chronic CTDP 31446 treatment

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Cocaine abuse remains a grave concern for the American, and increasingly the world, population. As no current therapeutic agents are available to assist cocaine addicts in achieving and maintaining abstinence it is important that new pharmacotherapies be developed. One important question not usually addressed in the development ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Nanotube Reagentless Proteomic Arrays

    SBC: EIC LABORATORIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The development of a new technology for reagentless multiplexed determination of protein concentrations in clinical and biological samples is proposed. The proposed approach employs nanotubes with molecular sized openings embedded within a mechanical and chemically robust polymeric membrane. We propose that a microarray may be constructed using these membranes ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. A lateral flow CD4 counting assay for resource-poor regions

    SBC: EPITYPE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The current need for routine measurement CD4+ cell counts of HIV-infected individual's is immense. Currently, the cost of CD4+ counting is a major issue (especially) in resource-poor environments, where the infection rates are highest. Cost of obtaining an accurate CD4+ count is not the only barrier to routine CD4+ monitoring in resource poor settings. Personn ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government